MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis

Overview of attention for article published in BMC Gastroenterology, January 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 9 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 977 followers.

MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis https://t.co/HusL5Uftit

22 Jan 2022

Reply Repost Favourite

New article: MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis https://t.co/wT3jrQGACc #livercancer #oncology https://t.co/ZZznLI721M

22 Jan 2022

Reply Repost Favourite

New article: MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis https://t.co/FffUIrX1kp #pancreaticcancer #oncology https://t.co/1BHZB7eXiR

22 Jan 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.